We are live on ! Find out more
AKCA

Akcea Therapeutics Inc
AKCA

Delisted

AKCA was delisted on the 9th of October, 2020.

Back to rankings

58 hedge funds and large institutions have $337M invested in Akcea Therapeutics Inc in 2017 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 19 increasing their positions, 14 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

217% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 6

36% more repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 14

29% more funds holding

Funds holding: 45 → 58 (+13)

30% less capital invested

Capital invested by funds: $480M → $337M (-$143M)

Holders
58
Holders Change
+13
Holders Change %
+28.89%
% of All Funds
1.32%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
19
Increased
19
Reduced
14
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BB
BB Biotech
Switzerland
+$24.5M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$23.8M
3
BlackRock
BlackRock
New York
+$19.4M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$2.06M
5
IHM
Iguana Healthcare Management
New York
+$1.96M

Top Sellers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$26.4M
2
Wellington Management Group
Wellington Management Group
Massachusetts
-$8.43M
3
OAM
Oxford Asset Management
United Kingdom
-$4.26M
4
ACM
Atika Capital Management
New York
-$2.49M
5
GIM
Granahan Investment Management
Massachusetts
-$2.23M
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$173M +$23.8M +1,212,675 +14%
Wellington Management Group
2
Wellington Management Group
Massachusetts
$48.5M -$8.43M -430,066 -13%
BlackRock
3
BlackRock
New York
$31.7M +$19.4M +988,200 +118%
BB
4
BB Biotech
Switzerland
$21.7M +$24.5M +1,248,650 New
Vanguard Group
5
Vanguard Group
Pennsylvania
$20.5M +$2.06M +105,135 +10%
EAM
6
Eventide Asset Management
Massachusetts
$7.29M – – –
State Street
7
State Street
Massachusetts
$4.46M +$1.8M +91,996 +56%
Geode Capital Management
8
Geode Capital Management
Massachusetts
$3.55M +$61.7K +3,147 +2%
GIM
9
Granahan Investment Management
Massachusetts
$3.37M -$2.23M -113,835 -37%
Northern Trust
10
Northern Trust
Illinois
$2.92M +$99.1K +5,056 +3%
AGA
11
Altrinsic Global Advisors
Connecticut
$2.6M +$490K +25,000 +20%
CS
12
Candriam SCA
Luxembourg
$1.99M -$1.52M -77,487 -40%
IHM
13
Iguana Healthcare Management
New York
$1.74M +$1.96M +100,000 New
Charles Schwab
14
Charles Schwab
California
$1.18M +$156K +7,957 +13%
USAA
15
United Services Automobile Association
Texas
$1.16M -$610K -31,100 -32%
Bank of New York Mellon
16
Bank of New York Mellon
New York
$1.11M +$254K +12,968 +25%
TCIM
17
TIAA CREF Investment Management
New York
$815K -$376K -19,189 -29%
ProShare Advisors
18
ProShare Advisors
Maryland
$661K +$747K +38,076 New
Deutsche Bank
19
Deutsche Bank
Germany
$600K +$101K +5,134 +17%
Goldman Sachs
20
Goldman Sachs
New York
$598K +$676K +34,463 New
Morgan Stanley
21
Morgan Stanley
New York
$583K +$195K +9,964 +42%
Wells Fargo
22
Wells Fargo
California
$563K +$478K +24,389 +305%
OAM
23
Oxford Asset Management
United Kingdom
$496K -$4.26M -217,198 -89%
Swiss National Bank
24
Swiss National Bank
Switzerland
$491K +$555K +28,300 New
CS
25
Credit Suisse
Switzerland
$482K +$347K +17,701 +176%
1
2 3

AKCA Hedge Fund Activity: Q4 2017 in Review

58 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in Akcea Therapeutics Inc (AKCA) for Q4 2017, worth a combined $337M — down 30% from $480M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new AKCA positions and 6 closed out — a net gain of 13 holders — while 19 added to existing stakes and 14 trimmed.

The largest buyer was BB Biotech, opening a new position worth an estimated $24.5M. The largest seller was T. Rowe Price Associates, exiting entirely with an estimated $26.4M sold.

  • 58 institutional investors held Akcea Therapeutics Inc (AKCA) as of Q4 2017, up from 45 in Q3 2017.
  • Funds reported $337M of Akcea Therapeutics Inc stock for Q4 2017, down 30% quarter-over-quarter.
  • 19 funds opened new Akcea Therapeutics Inc positions in Q4 2017 and 6 closed out, a net change of +13 holders.
  • The largest Akcea Therapeutics Inc buyer in Q4 2017 was BB Biotech, an estimated $24.5M added.
  • The largest Akcea Therapeutics Inc seller in Q4 2017 was T. Rowe Price Associates, an estimated $26.4M sold.

Based on aggregated 13F filings for Q4 2017.